Klastersky J, Coppens L, Meunier-Carpentier F, Menday A P
Antimicrob Agents Chemother. 1980 Sep;18(3):437-42. doi: 10.1128/AAC.18.3.437.
Mecillinam or a placebo was added to a combination of cefazolin and carbenicillin as an early therapy of septicemia caused by gram-negative organisms in patients with serious underlying diseases, none of whom was neutropenic, however. Patients in whom infection was caused by pathogens against which mecillinam and cefazolin or mecillinam and carbenicillin were synergistic might have responded more often than patients treated with nonsynergistic combinations. However, overall results did not show any benefit from combining mecillinam with cefazolin and carbenicillin. This study suggests that in nonneutropenic patients with septicemia caused by gram-negative organisms, there is no need to intensify antimicrobial therapy beyond a certain point of efficacy. The measurement of the bactericidal activity in the serum of treated patients might serve as guide for adequate therapy.
在患有严重基础疾病的患者中,美西林或安慰剂被添加到头孢唑林和羧苄青霉素的联合用药中,作为革兰氏阴性菌引起的败血症的早期治疗方法,不过这些患者均无中性粒细胞减少症。感染由对美西林与头孢唑林或美西林与羧苄青霉素有协同作用的病原体引起的患者,其反应可能比接受非协同联合用药治疗的患者更频繁。然而,总体结果并未显示美西林与头孢唑林和羧苄青霉素联合使用有任何益处。本研究表明,在非中性粒细胞减少的革兰氏阴性菌败血症患者中,无需在一定疗效点之外强化抗菌治疗。测定接受治疗患者血清中的杀菌活性可能有助于指导适当的治疗。